Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 9/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 8/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4241954 | 1.00 | TLR7 (0.39) | TLR7TLR8DYRK1ARAB9AATM | |
| SCHEMBL16188204 | 0.88 | TLR7 (0.35) | TLR7TLR8 | |
| SCHEMBL4239847 | 0.87 | TLR7 (0.42) | TLR7TLR8RAB9AATMACSS2 | |
| SCHEMBL4245720 | 0.87 | TLR7 (0.41) | TLR7TLR8ACSS2 | |
| SCHEMBL4245726 | 0.87 | TLR7 (0.41) | TLR7TLR8ACSS2 | |
| SCHEMBL1486770 | 0.86 | TLR7 (0.39) | TLR7TLR8RAB9AACSS2MAPT | |
| SCHEMBL4239486 | 0.85 | TLR8 (0.41) | TLR7TLR8DYRK1A | |
| SCHEMBL4241542 | 0.82 | TLR7 (0.56) | TLR7TLR8 | |
| SCHEMBL4252899 | 0.79 | TLR7 (0.42) | TLR7TLR8DYRK1AACSS2 | |
| SCHEMBL1486717 | 0.78 | TOP2A (0.36) | TLR7TLR8ACSS2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856254-B2 | Alkoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160280707-A1 | ALKOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2016-09-29 | — | — | US | disclosed |
| US-9365567-B2 | Alkoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2016-06-14 | — | — | US | disclosed |
| EP-1673087-B1 | ALKOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2015-05-13 | — | — | EP | disclosed |
| US-20150023990-A1 | ALKOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY | 2015-01-22 | — | — | US | disclosed |
| EP-1673087-A4 | ALKOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2009-04-08 | — | — | EP | disclosed |
| US-20070060754-A1 | Alkoxy substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-03-15 | — | — | US | disclosed |
| EP-1673087-A2 | ALKOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005032484-A2 | ALKOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150023990-A1 | ALKOXY SUBSTITUTED IMIDAZOQUINOLINES | IL2, IFNG, IRF3 | TLR7 36/4885TLR8 129/4885DYRK1A 4561/4885 |
| US-20070060754-A1 | Alkoxy substituted imidazoquinolines | IL2, IFNG, IRF3 | TLR7 36/4885TLR8 129/4885DYRK1A 4561/4885 |
| US-20160280707-A1 | ALKOXY SUBSTITUTED IMIDAZOQUINOLINES | IL2, IFNG, IRF3 | TLR7 36/4885TLR8 129/4885DYRK1A 4561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.